Additionally, with the goal of stratifying patients by predictive markers for outcomes, starting with known markers, including cyclin D1 the main driver in MCL, the G/A870 cyclin D1 polymorphism, relevant gene expression profiles such as Sox11 and TP53 after treatment and anti-CD20 maintenance therapy were correlated with treatment response in MCL [19, 20]. The gene discussed is MS4A1; the disease is mantle cell lymphoma.